National Physical Laboratory (NPL) has announced the launch of a new piece of medical technology aimed at improving the success rates of radiotherapy cancer treatments. The new clinical electron linear accelerator (linac) will help ensure patients are treated with accurate doses of radiation. NPL’s new clinical linac’s ability to provide highly stable beams and accurate doses will enable calibrations with smaller uncertainties. This will allow hospitals to deliver more accurate, and more effective, radiation doses to cancer patients.

The U.S. Food and Drug Administration has granted approval for an Abbreviated New Drug Application for Akorn-Strides‘ Pamidronate Disodium Injection, 3 mg/mL and 9 mg/mL in 10 mL vials. The joint venture between Akorn and Strides was formed to develop liquid, dry powder and lyophilized formulations of generic injectable pharmaceuticals for a wide market with focus on painkillers, anti-infectives and CNS medications. Pamidronate Disodium Injection has received the indication for use in the treatment of hypercalcemia related to tumors and Paget’s disease.